<?xml version="1.0" encoding="UTF-8"?>
<p>AK-0529 is a novel compound being developed to inhibit RSV replication by blocking viral entry into the target cells. A placebo-controlled phase 1 clinical trial showed that oral administration of this antiviral is well tolerated among healthy volunteers and meets the standard safety profile (
 <xref rid="ref146" ref-type="bibr">Toovey et al., 2015</xref>). A phase 2 clinical trial in hospitalized infants infected with RSV is currently underway (NCT02654171).
</p>
